← brief for 2026-08-12 · Slowing decline

Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial — NephJC

Key takeaways

This trial compared two treatments for primary membranous nephropathy, a disease where the kidney's filter is damaged and leaks protein into the urine. People were randomly assigned to get either obinutuzumab, an antibody given by drip, or tacrolimus, a pill that calms the immune system. It was a head-to-head test to see which better controls the disease, published in a top journal (NEJM). Because it is a mid-size trial, it shows which drug worked better here but does not settle long-term kidney survival.

Source

Page · Forager · 2026-08-13
https://www.nephjc.com/news/2026/06/22-majestyobi